Novozymes is based on bioinnovation. This means we apply biotechnology to challenge and complement traditional thinking and applications to find sustainable solutions for forward-looking companies.
Our core business
Our core business is industrial enzymes, microorganisms, and biopharmaceutical ingredients. Novozymes employs in-house projects, strategic alliances, and acquisitions to enter new business areas.
Research resources
Novozymes invests 14% of revenue in research and development. Enzymes receive the bulk of our research resources while the balance is used for microorganisms and other areas outside enzymes. In these areas we leverage our biotech competencies and technologies to deliver solutions to the biopharmaceutical industry, among others. Using our existing competencies, we are exploring new business opportunities based on our core technologies, fermentation, and the production of proteins.
Long-term targets
Financial targets:
- Annual organic sales growth of more than 10%
- Operating profit margin of more than 20%
- Annual Return on invested capital (ROIC) of more than 22%
Sustainability targets:
- Enable a 75 million ton reduction in CO2 emissions per year by 2015 through our customers' application of our products
- Improve energy efficiency by 50% in 2015 compared to 2005
- Reduce our CO2 emissions by 50% in 2015 compared to 2005
- Increase energy supply from renewable and CO2-neutral sources to 50% in 2020
- Improve water efficiency by 40% in 2015 compared to 2005
- Be recognized as a global leader within sustainability
- Be a preferred employer globally
Patents
Novozymes has an extensive patent portfolio with more than 6,000 active patents, patent
applications, and licensed patents. We continuously and proactively seek partners to license or in-license patents within our interest areas.